HealthEquity (NASDAQ:HQY) Releases FY 2025 Earnings Guidance

HealthEquity (NASDAQ:HQY) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 3.080-3.160 for the period, compared to the consensus estimate of 3.120. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. HealthEquity also updated its FY 2026 guidance to EPS.

HealthEquity Trading Up 0.8 %

HealthEquity stock traded up $0.79 during mid-day trading on Monday, hitting $101.00. The stock had a trading volume of 1,220,609 shares, compared to its average volume of 626,324. The stock has a 50-day simple moving average of $92.42 and a two-hundred day simple moving average of $83.64. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $8.82 billion, a PE ratio of 84.53, a P/E/G ratio of 1.57 and a beta of 0.55. HealthEquity has a 12 month low of $62.10 and a 12 month high of $105.82.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HQY. Royal Bank of Canada reiterated an “outperform” rating and set a $92.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Mizuho began coverage on shares of HealthEquity in a research report on Wednesday, December 4th. They set an “outperform” rating and a $126.00 target price for the company. Barrington Research increased their price target on HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. JMP Securities reissued a “market outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $109.64.

Insider Transactions at HealthEquity

In other HealthEquity news, Director Frank Corvino sold 1,247 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the completion of the transaction, the director now directly owns 4,823 shares in the company, valued at $387,093.98. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert W. Selander sold 8,250 shares of the stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the sale, the director now owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. This represents a 13.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock valued at $884,517 in the last ninety days. 2.20% of the stock is currently owned by corporate insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.